BIOPOA

About BIOPOA

BIOPOA is a biopharmaceutical research and development company specializing in vaccine development and diagnostic technology for both humans and animals. Founded in February 2007 by CEO Sun Hee Cho, the company is headquartered in Hwaseong, South Korea. Sun Hee Cho holds a Doctor of Veterinary Microbiology from Seoul National University and has an extensive background in molecular biology, DNA vaccine development, and molecular diagnostics from institutions like KIST, Seoul National University's Cancer Research Institute, and Green Cross Corp.

The company's core technological competency lies in reverse genetics and Synthetic Attenuated Virus Engineering (SAVE), which it applies to the development of ideal viral vaccines through gene recombination. This technology underpins its product pipeline, which includes vaccines for both human and animal diseases. Notable products include treatments for Porcine Reproductive and Respiratory Syndrome (PRRS), COVID-19, and Newcastle Disease Virus (NDV). The company develops NDV vector vaccines for various applications, including for Highly Pathogenic Avian Influenza (HPAI) and as an oncolytic (cancer-fighting) vaccine. In addition to vaccines, BIOPOA produces diagnostic kits, such as real-time PCR and LAMP kits for COVID-19.

BIOPOA's business model involves the research, development, manufacturing, and commercialization of its biopharmaceutical products. The company has received investments from venture capital firms and strategic partners, including Yuhan Corporation, Agricultural Corporation Joining, and the Harim Group. Significant milestones include receiving KVGMP (Korea Veterinary Good Manufacturing Practice) approval, obtaining CE certification for its COVID-19 diagnostic kit, and exporting these kits internationally. The company is preparing for an Initial Public Offering (IPO) and continues to focus on technological innovation to serve the global One Health market, aiming to improve the health of both humans and animals.